Chrysin prevents inflammation-coinciding liver steatosis via AMPK signalling.

This article investigates the therapeutic potential of Chrysin (CN), a natural flavonoid, in treating non-alcoholic fatty liver disease (NAFLD) induced by a high-fat diet (HFD) in mice. The study demonstrates that CN administration reduces liver fat accumulation, inflammation, fibrosis, and liver toxicity markers, while improving obesity and metabolic parameters. Mechanistically, CN activates AMP-activated protein kinase (AMPK) signaling, leading to decreased lipogenesis via downregulation of SREBP1c and increased phosphorylation of acetyl-CoA carboxylase (ACC), and concurrently inhibits NLRP3 inflammasome activation, reducing inflammation. Proteomic analyses further reveal that CN modulates liver protein expression profiles by enhancing pathways related to lipid metabolism, fatty acid oxidation, and energy conversion, while suppressing immune and inflammatory responses. These findings suggest CN as a promising candidate for NAFLD treatment through coordinated regulation of metabolic and inflammatory pathways.